SUDEP
Alica Goldman, MD, PhD / Baylor College of Medicine
We will perform whole genome sequencing on DNA samples from patients that died of SUDEP, SCD, and SIDS to understand the genomic variation in cardiac, respiratory or autonomic pathways and we will use bioinformatic analyses to understand the point of overlap in these genetic networks.
CURE Award
Erik Rytting, PhD / University of Texas, Galveston
The goal of this project is to develop nanoparticles that will accumulate in the brain to treat the epilepsy and thereby reduce the amount of medication crossing the placenta and affecting the baby’s development.
Innovator Award, in Honor of CURE 365
Nicola Marchi, PhD / CNRS Delegation Regionale Languedoc Roussillon, France
We propose that a key brain vasculature receptor called PDGFRb regulates the brain’s blood flow response to seizures, and we will explore whether modulation of the receptor using specific medications can stop seizures.
Taking Flight Award
Omar Ahmed, PhD / Brown University
Our goal is to prevent seizures by helping individual brain cells self-regulate their own activity, without the need for invasive electrodes, monitoring devices or implanted batteries.
Innovator Award, Funded by the Julie's Hope Award
Antonello Mallamaci, PhD / Scuola Internazionale Superiore di Studi Avanzati, Trieste, Italy
If successful, this approach will be exploitable for scalable, personalized cures of epileptogenic gene loss.
Innovator Award
Marta Biagioli, PhD / University of Trento, Trento, Italy
This proposal aims to demonstrate how SINEUP can rescue the protein deficit and treat the disease.
Taking Flight Award
Kenneth Myers, MD, PhD / University of Melbourne/Austin Health
The ultimate goal is to generate data that can be used to design a rapid genetic testing protocol that will help doctors choose a medication for CAE based on an individual’s genetics, taking a step closer to precision medicine.
Taking Flight Award
Rene Barro Soria, PhD / University of Miami
The goals of the present research project are a) to define the molecular basis of voltage activation of IKM channels, to understand the mechanisms by which epilepsy causing mutations affect IKM channels function and b) to design new drugs for the treatment of these IKM channelopathies.
CURE Epilepsy Award
Stephen Traynelis, PhD / Emory University
They will monitor seizure type and frequency, EEG, and developmental assessment before and after off-label treatment with FDA-approved NMDAR inhibitors.
